Compare GSK plc (GSK) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs McCormick & Company, Incorporated — how do they compare? GSK plc trades at $52.36 (market cap $101.34B), while McCormick & Company, Incorporated trades at $52.15 (market cap $13.70B). The key difference: GSK plc is far larger — about 7.4× McCormick & Company, Incorporated's market cap, and McCormick & Company, Incorporated pays the higher dividend (3.77%). Which is the better fit depends on your goals.
| GSK | MKC | |
|---|---|---|
Market Cap | $101.34B | $13.70B |
Sector | Health | Consumer Staples |
52-Week High | $61.18 | $72.81 |
52-Week Low | $36.20 | $45.60 |
Enterprise Value | $121.95B | $18.30B |
Dividend Yield | 3.49% | 3.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
McCormick (MKC) trades at $52.85, down 1.67% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $59.67. The company reported strong Q2 2026 earnings of $0.80 per share, beating estimates, driven by acquisitions and margin expansion. Recent news highlights the transformative potential of the Unilever Foods deal, while financials show steady revenue growth and a net income margin of 21.91% for 2025.
The outlook is positive with 36.67% of analysts rating it a buy, citing undervaluation and strategic deals, but risks include soft consumer volumes and integration challenges. Upside hinges on execution of cost savings and volume recovery, with the current P/E of 8.47 suggesting value if growth accelerates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
